Ketamine used as an acesodyne in human breast cancer therapy causes an undesirable side effect, upregulating anti-apoptosis protein Bcl-2 expression

Genetics and Molecular Research

Volumn 12, Issue 2, 2013, Pages 1907-1915

  He, H ^a   Chen, J ^a   Xie, W P ^b   Cao, S ^a   Hu, H Y ^a   Yang, L Q ^c   Gong, B ^a  

^a Shanghai Changning Maternity and Infant Health Hospital   (China)

^b Shanghai Municipal TCM Hospital   (China)

^c NANCHANG UNIVERSITY   (China)

Author keywords

Bcl 2; Breast cancer; Ketamine

Indexed keywords

KETAMINE; PROTEIN BCL 2;

APOPTOSIS; ARTICLE; BREAST CANCER; CANCER CELL CULTURE; CANCER PAIN; CANCER PATIENT; CELL PROLIFERATION; CELL STRAIN MDA MB 231; CONTROLLED STUDY; DISEASE EXACERBATION; DRUG CHOICE; DRUG SAFETY; GENE SILENCING; HUMAN; HUMAN CELL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REAL TIME POLYMERASE CHAIN REACTION; TUMOR INVASION; UPREGULATION;

BREAST NEOPLASMS; CELL LINE, TUMOR; CELL PROLIFERATION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENE KNOCKDOWN TECHNIQUES; HUMANS; KETAMINE; NEOPLASM INVASIVENESS; PROTO-ONCOGENE PROTEINS C-BCL-2; UP-REGULATION;

EID: 84877308839     PISSN: None     EISSN: 16765680     Source Type: Journal    
DOI: 10.4238/2013.January.4.7     Document Type: Article

References (26)

1. Adams JM and Cory S (1998). The Bcl-2 protein family: arbiters of cell survival. Science 281: 1322-1326.
2. Andrews GA, Xi S, Pomerantz RG, Lin CJ, et al. (2004). Mutation of p53 in head and neck squamous cell carcinoma correlates with Bcl-2 expression and increased susceptibility to cisplatin-induced apoptosis. Head Neck 26: 870-877.
3. Backonja M, Arndt G, Gombar KA, Check B, et al. (1994). Response of chronic neuropathic pain syndromes to ketamine: a preliminary study. Pain 56: 51-57.
4. Bell R, Eccleston C and Kalso E (2003). Ketamine as an adjuvant to opioids for cancer pain. Cochrane Database Syst. Rev. CD003351.
5. Borner C (2003). The Bcl-2 protein family: sensors and checkpoints for life-or-death decisions. Mol. Immunol. 39: 615-647.
6. Clark JL and Kalan GE (1995). Effective treatment of severe cancer pain of the head using low-dose ketamine in an opioid-tolerant patient. J. Pain Symptom Manage 10: 310-314.
7. Fanidi A, Harrington EA and Evan GI (1992). Cooperative interaction between c-myc and bcl-2 proto-oncogenes. Nature 359: 554-556.
8. Felsby S, Nielsen J, Arendt-Nielsen L and Jensen TS (1996). NMDA receptor blockade in chronic neuropathic pain: a comparison of ketamine and magnesium chloride. Pain 64: 283-291.
9. Fernandez-Sarabia MJ and Bischoff JR (1993). Bcl-2 associates with the ras-related protein R-ras p23. Nature 366: 274-275.
10. Haldar S, Beatty C, Tsujimoto Y and Croce CM (1989). The bcl-2 gene encodes a novel G protein. Nature 342: 195-198.
11. Hockenbery DM, Oltvai ZN, Yin XM, Milliman CL, et al. (1993). Bcl-2 functions in an antioxidant pathway to prevent apoptosis. Cell 75: 241-251.
12. Ikegaki N, Katsumata M, Minna J and Tsujimoto Y (1994). Expression of bcl-2 in small cell lung carcinoma cells. Cancer Res. 54: 6-8.
13. Ilkjaer S, Petersen KL, Brennum J, Wernberg M, et al. (1996). Effect of systemic N-methyl-D-aspartate receptor antagonist (ketamine) on primary and secondary hyperalgesia in humans. Br. J. Anaesth. 76: 829-834.
14. Krajewski S, Krajewska M, Ehrmann J, Sikorska M, et al. (1997). Immunohistochemical analysis of Bcl-2, Bcl-X, Mcl-1, and Bax in tumors of central and peripheral nervous system origin. Am. J. Pathol. 150: 805-814.
15. McCall TD, Pedone CA and Fults DW (2007). Apoptosis suppression by somatic cell transfer of Bcl-2 promotes Sonic hedgehog-dependent medulloblastoma formation in mice. Cancer Res. 67: 5179-5185.
16. Mercadante S, Arcuri E, Tirelli W and Casuccio A (2000). Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J. Pain Symptom Manage 20: 246-252.
17. Monni O, Joensuu H, Franssila K, Klefstrom J, et al. (1997). BCL2 overexpression associated with chromosomal amplification in diffuse large B-cell lymphoma. Blood 90: 1168-1174.
18. Robertson LE, Plunkett W, McConnell K, Keating MJ, et al. (1996). Bcl-2 expression in chronic lymphocytic leukemia and its correlation with the induction of apoptosis and clinical outcome. Leukemia 10: 456-459.
19. Roytblat L, Korotkoruchko A, Katz J, Glazer M, et al. (1993). Postoperative pain: the effect of low-dose ketamine in addition to general anesthesia. Anesth. Analg. 77: 1161-1165.
20. Sentman CL, Shutter JR, Hockenbery D, Kanagawa O, et al. (1991). bcl-2 inhibits multiple forms of apoptosis but not negative selection in thymocytes. Cell 67: 879-888.
21. Slatkin NE and Rhiner M (2003). Ketamine in the treatment of refractory cancer pain: case report, rationale, and methodology. J. Support. Oncol. 1: 287-293.
22. Sorensen J, Bengtsson A, Backman E, Henriksson KG, et al. (1995). Pain analysis in patients with fibromyalgia. Effects of intravenous morphine, lidocaine, and ketamine. Scand. J. Rheumatol. 24: 360-365.
23. Stegh AH, Chin L, Louis DN and DePinho RA (2008). What drives intense apoptosis resistance and propensity for necrosis in glioblastoma? A role for Bcl2L12 as a multifunctional cell death regulator. Cell Cycle 7: 2833-2839.
24. Strik H, Deininger M, Streffer J, Grote E, et al. (1999). BCL-2 family protein expression in initial and recurrent glioblastomas: modulation by radiochemotherapy. J. Neurol. Neurosurg. Psychiatr. 67: 763-768.
25. Warncke T, Stubhaug A and Jorum E (1997). Ketamine, an NMDA receptor antagonist, suppresses spatial and temporal properties of burn-induced secondary hyperalgesia in man: a double-blind, cross-over comparison with morphine and placebo. Pain 72: 99-106.
26. Wong CS, Lu CC, Cherng CH and Ho ST (1997). Pre-emptive analgesia with ketamine, morphine and epidural lidocaine prior to total knee replacement. Can. J. Anaesth. 44: 31-37.